# Oncologic Drugs Advisory Committee; Notice of Meeting
**AGENCY:**
Food and Drug Administration, HHS.
**ACTION:**
Notice.
This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.
*Name of Committee* : Oncologic Drugs Advisory Committee.
*General Function of the Committee* : To provide advice and recommendations to the agency on FDA's regulatory issues.
*Date and Time* : The meeting will be held on February 27, 2002, from 8 a.m. to 5:30 p.m.
*Location* : Holiday Inn, Versailles Ballroom, 8120 Wisconsin Ave., Bethesda, MD.
*Contact* : Karen M. Templeton-Somers, Center for Drug Evaluation and Research (HFD-21), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-7001, e-mail: [email protected], or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), code 12542. Please call the Information Line for up-to-date information on this meeting.
*Agenda* : The committee will discuss: (1) Trial design considerations and appropriate patient populations for studies of investigational agents for adjuvant therapy of melanoma given the availability of an approved agent for this indication; and (2) the appropriate study design and control for the proposed phase 3 trial of investigational new drug (IND) 2885, MELACINE (melanoma vaccine), Corixa Corp., for adjuvant treatment of melanoma.
*Procedure* : Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by February 20, 2002. Oral presentations from the public will be scheduled between approximately 8:15 a.m. and 8:45 a.m., and 1:15 p.m. and 1:45 p.m. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before February 20, 2002, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation. After the scientific presentations, a 30-minute open public session may be conducted for interested persons who have submitted their request to speak by February 20, 2002, to address issues specific to the topic before the committee.
Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).
Dated: January 18, 2002.
Linda A. Suydam,
Senior Associate Commissioner.